Stragen
Caroline D. has a strong background in quality assurance and regulatory affairs within the pharmaceutical industry. Caroline'smost recent role is as the Head of Quality - Responsible Person at Stragen, starting in May 2021. Prior to this, they worked as an Independent GMP/QA Senior Expert Consultant at C. Drouet since April 2018. From July 2015 to January 2021, they were the Head of Quality Assurance at Teoxane Laboratories Geneva, where they managed the laboratories' quality control, development, and stability studies. Before that, Caroline worked as a Pharmacist and the Head of Development Lab at Galderma from January 2013 to July 2015, and as the Head of the Development unit and Regulatory Affairs Pharmacist at Laboratoire Boiron from February 2011 to January 2013. Caroline also held the role of Regulatory Affairs Pharmacist and Manager of the Analytical Development Department at Boiron from July 2008 to February 2011, and started their career as a Regulatory Affairs Pharmacist at Laboratoire Boiron from September 2005 to July 2008.
Caroline D. obtained their Doctorate in Pharmacy from Faculté de pharmacie, Université Joseph Fourier (Grenoble I) in the years 2000 to 2005. Following this, they pursued a Master's degree in Quality Control and Quality Assurance at Institut de la pharmacie industrielle de Lyon (IPIL) from 2005 to 2006. During the same period, they also completed a Master 2 (M2) in Management at emlyon business school. There is no specific information available regarding their education after 2006, as the start and end years are not provided for their enrollment at LGM.
This person is not in any offices
Stragen
Focusing on innovation for health solutions since 1990, Stragen is a global player in the development, registration and distribution of Generic drugs and Consumer Health products. Starting as a small API trading platform 30 years ago in Geneva, Switzerland, today Stragen operates in over 60 markets through a network of dynamic and collaborative partners, employing over 150 people and working with 10 dedicated affiliates worldwide. As a result of decades of experience and expertise in R&D, combined with our continuous commitment to advancing public health, we invest in the fundamental research through to the delivery of innovative and trusted health solutions to address unmet medical needs. We focus on two core activities: • Selected and Advanced Generics • Consumer Health products Our specialized and passionate scientific team consistently operates under the latest quality standards to deliver Swiss tailor-made solutions with the final product 100% manufactured in Europe. At Stragen, we understand that business models need to be reinvented to work within our competitive and fast-changing environment of the Pharma industry. We have identified how we can positively diversify our activities beyond the historical development and licensing out of Generic+ products, to the development of Consumer Health products as well as the development through to proof of concept of patented new drugs.